This book covers the latest advances in non-muscle invasive bladder cancer care. It provides a review of the available evidence base for the efficacy of a range of therapeutic techniques, diagnostic procedures and risk factors. Management of Non-Muscle Invasive Bladder Cancer features detailed guidance in uniformly formatted chapters on how to properly apply a range of available therapeutic treatments relevant for patient care. It is a valuable resource for all trainee and practising medical professionals who treat these patients.
This book presents state-of-the-art diagnoses and treatments available for bladder cancer that has metastasised into the body.
Of the three types of bladder cancer, Non-Muscle Invasive Bladder Cancer (NMIBC) is the most common form and is diagnosed in over 70% of cases.
Of the three types of bladder cancer, Non-Muscle Invasive Bladder Cancer (NMIBC) is the most common form and is diagnosed in over 70% of cases.
This book covers the application of chemotherapy for muscle invasive and advanced disease. The evidence-based application of multimodality therapy is highlighted.
This book provides an overview of the most hotly debated areas in bladder cancer. Authors have focused on the emerging role of markers for NMI UC and various ways of improving the efficacy of current chemotherapy in the first section.
When are they best used? What is the optimal sequence of treatments for individual patients? This third edition of 'Fast Facts: Bladder Cancer' has been updated extensively throughout by two new authors, bringing a fresh perspective.
The American Urological Association Report on the Management of Non-Muscle-Invasive Bladder Cancer (Stages Ta, T1 and Tis)
UROLOGIC CLINICS OF NORTH AMERICA This page intentionally left blank Preface Intravesical Therapy for Nonmuscle. FORTHCOMING ISSUES RECENT ISSUES May 2020 Male Infertility James Hotaling, Editor August 2020 Cancer Immunotherapy in ...
This book provides a comprehensive overview of contemporary evidence-based management of urothelial carcinoma.
However, HAL (marketed as Hexvix/Cyview by Photocure, Norway) is the only agent approved in both the United States (FDA approved in 2010) and Europe (2005), so we will center our discussion on this formulation. mucosal folds [17], ...